|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | A61K 31/00 | |
| A61K 31/502 | |||
| A61P 35/00 |
| (11) | Patento numeris | 2305221 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10178515.2 |
| Europos patento paraiškos padavimo data | 2004-11-30 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-04-06 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2015-05-20 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 526244 P | 2003-12-01 | US | |
| 0327844 | 2003-12-01 | GB |
| (72) |
Ashworth, Alan, GB
Jackson, Stephen, GB
Martin, Niall, GB
Smith, Graeme, GB
|
| (73) |
Kudos Pharmaceuticals Limited,
2 Kingdom Street, London W2 6BD,
GB
The Institute of Cancer Research, 123 Old Brompton Road, London, Greater London SW7 3RP, GB |
| (54) | DNA damage repair inhibitors for treatment of cancer |
| DNA damage repair inhibitors for treatment of cancer |